ACS MedChem Lett | Cambridge MedChem Consulting
Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist | ACS Medicinal Chemistry Letters
ACS Med Chem Lett (@ACSMedChemLett) / Twitter
ACS Publications - ACS Medicinal Chemistry Letter is soliciting papers on technological advances in medicinal chemistry and drug development. Learn more about the call for papers and be sure to submit your
Featured Letter in ACS Medicinal Chemistry Letters – NITSCHE LAB
Author Guidelines
ACS Med Chem Lett Paper Accepted!
ACS Medicinal Chemistry Letters | Vol 11, No 11
ACS Medicinal Chemistry Letters | Vol 11, No 10
ACS Med Chem Lett (@ACSMedChemLett) / Twitter
An Innovation 10 Years in the Making: The Stories in the Pages of ACS Medicinal Chemistry Letters | ACS Medicinal Chemistry Letters
Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation | ACS Medicinal Chemistry Letters
IRBM's drug discovery research is featured on the cover of this issue's ACS Publications' Medicinal Chemistry Letters - IRBM
ACS Medicinal Chemistry Letters: Volume 11, Issue 5
Our collaborative work with Scott Lokey's Lab at UCSC on PROTAC structure-permeability relationships is now published in ACS Med Chem Lett | Ciulli Laboratory
ACS Medicinal Chemistry Letters Impact Factor:... | Exaly
Massively Parallel Optimization of the Linker Domain in Small Molecule Dimers Targeting a Toxic r(CUG) Repeat Expansion | ACS Medicinal Chemistry Letters
Discovery and Optimization of Potent, Selective, and in Vivo Efficacious 2-Aryl Benzimidazole BCATm Inhibitors | ACS Medicinal Chemistry Letters
Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C | ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters: Innovations Webinar - YouTube
ACS Med. Chem. Lett. | PROTAC targeted FLT3 - ITD proteins: new therapy of acute myeloid leukemia
ACS Med Chem Lett (@ACSMedChemLett) / Twitter
![Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-a]pyridinones as Topoisomerase IIα-Inhibiting Anticancer Agents | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.6b00242/asset/images/acsmedchemlett.6b00242.social.jpeg_v03 "Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-a]pyridinones as Topoisomerase IIα-Inhibiting Anticancer Agents | ACS Medicinal Chemistry Letters")
Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-a]pyridinones as Topoisomerase IIα-Inhibiting Anticancer Agents | ACS Medicinal Chemistry Letters
ACS Med Chem 2011 (2) 919-923
A 2020 publication from our PhD student Eleonora Cescon (Cycle 35, Department of Chemical and Pharmaceutical Sciences, UniTS) on ACS Med. Chem. Lett. | Doctoral Programme
